{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:26:59Z","timestamp":1792718819040,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s12185-021-03217-4","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T17:37:40Z","timestamp":1630949860000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation"],"prefix":"10.1007","volume":"115","author":[{"given":"Akihiko","family":"Izumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-4459","authenticated-orcid":false,"given":"Takayoshi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiwa","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"issue":"6","key":"3217_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/leu.2011.351","volume":"26","author":"A Spyridonidis","year":"2012","unstructured":"Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia. 2012;26(6):1211\u20137.","journal-title":"Leukemia"},{"issue":"10","key":"3217_CR2","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Stanze D, Beck J, Diedrich H, Horst HA, H\u00fcttmann A, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032\u201341.","journal-title":"Blood"},{"issue":"1","key":"3217_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/bjh.12225","volume":"161","author":"S Kako","year":"2013","unstructured":"Kako S, Kanamori H, Kobayashi N, Shigematsu A, Nannya Y, Nakamae M, et al. Outcome after first relapse in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia. Br J Haematol. 2013;161(1):95\u2013103.","journal-title":"Br J Haematol"},{"issue":"8","key":"3217_CR4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353.","journal-title":"N Engl J Med"},{"issue":"14","key":"3217_CR5","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, G\u00f6kbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474\u201387.","journal-title":"Cancer"},{"issue":"9","key":"3217_CR6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836\u201347.","journal-title":"N Engl J Med"},{"issue":"16","key":"3217_CR7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"issue":"19","key":"3217_CR8","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. Phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u201396.","journal-title":"N Engl J Med"},{"issue":"8","key":"3217_CR9","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","volume":"4","author":"HM Kantarjian","year":"2017","unstructured":"Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017;4(8):e387\u201398.","journal-title":"Lancet Haematol"},{"issue":"6","key":"3217_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12185-019-02749-0","volume":"110","author":"N Fujishima","year":"2019","unstructured":"Fujishima N, Uchida T, Onishi Y, Jung CW, Goh YT, Ando K, et al. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed\/refractory acute lymphoblastic leukemia. Int J Hematol. 2019;110(6):709\u201322.","journal-title":"Int J Hematol"},{"issue":"16","key":"3217_CR11","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.2169\/internalmedicine.4440-20","volume":"59","author":"M Okura","year":"2020","unstructured":"Okura M, Ida N, Yamauchi T. Clinical significance of inotuzumab ozogamicin in non-transplant patients with relapsed acute lymphoblastic leukemia: a report of four cases. Intern Med. 2020;59(16):2047\u201351.","journal-title":"Intern Med"},{"key":"3217_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-1-60761-629-0_13","volume":"630","author":"H Fan","year":"2010","unstructured":"Fan H, Robetorye RS. Real-time quantitative reverse transcriptase polymerase chain reaction. Methods Mol Biol. 2010;630:199\u2013213.","journal-title":"Methods Mol Biol"},{"issue":"6","key":"3217_CR13","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","volume":"17","author":"VH van der Velden","year":"2003","unstructured":"van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17(6):1013\u201334.","journal-title":"Leukemia"},{"issue":"11","key":"3217_CR14","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1182\/blood-2006-01-015347","volume":"109","author":"A Ray","year":"2007","unstructured":"Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood. 2007;109(11):5011\u20135.","journal-title":"Blood"},{"issue":"7","key":"3217_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906\u201312.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"3217_CR16","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","volume":"4","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini\u2013hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4(2):230\u20134.","journal-title":"JAMA Oncol"},{"issue":"20","key":"3217_CR17","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1002\/cncr.31720","volume":"124","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, et al. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018;124(20):4044\u201355.","journal-title":"Cancer"},{"issue":"3","key":"3217_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.23901","volume":"90","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, O\u2019Brien S, Huang X, Thomas D, Rytting M, Sasaki K, et al. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015;90(3):193\u20136.","journal-title":"Am J Hematol"},{"issue":"10","key":"3217_CR19","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1158\/1078-0432.CCR-20-2399","volume":"27","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O\u2019Brien SM, et al. Inotuzumab ozogamicin for relapsed\/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22. Clin Cancer Res. 2021;27(10):2742\u201354.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3217_CR20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/curroncol28010027","volume":"28","author":"W Fingrut","year":"2020","unstructured":"Fingrut W, Davis W, McGinnis E, Dallas K, Ramadan K, Merkeley H, et al. Reevaluating patient eligibility for inotuzumab ozogamicin based on CD22 expression: is dim expression sufficient? Curr Oncol. 2020;28(1):252\u20139.","journal-title":"Curr Oncol"},{"issue":"10","key":"3217_CR21","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/cncr.31317","volume":"124","author":"HM Kantarjian","year":"2018","unstructured":"Kantarjian HM, Su Y, Jabbour EJ, Bhattacharyya H, Yan E, Cappelleri JC, et al. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed\/refractory acute lymphoblastic leukemia. Cancer. 2018;124(10):2151\u201360.","journal-title":"Cancer"},{"issue":"6","key":"3217_CR22","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1080\/10428194.2016.1243678","volume":"58","author":"T Tachibana","year":"2017","unstructured":"Tachibana T, Matsumoto K, Tanaka M, Hagihara M, Motohashi K, Yamamoto W, et al. Outcome and prognostic factors among patients who underwent a second transplantation for disease relapse post the first allogeneic cell transplantation. Leuk Lymphoma. 2017;58(6):1403\u201311.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"3217_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50(6):781\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"3217_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","volume":"25","author":"S Corbacioglu","year":"2019","unstructured":"Corbacioglu S, Jabbour EJ, Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant. 2019;25(7):1271\u201380.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"3217_CR25","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127(13):1656\u201365.","journal-title":"Blood"},{"issue":"5","key":"3217_CR26","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","volume":"102","author":"M Wadleigh","year":"2003","unstructured":"Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102(5):1578\u201382.","journal-title":"Blood"},{"issue":"5","key":"3217_CR27","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.bbmt.2019.12.763","volume":"26","author":"VT Ho","year":"2020","unstructured":"Ho VT, Martin AS, P\u00e9rez WS, Steinert P, Zhang MJ, Chirnomas D, et al. Prior Gemtuzumab ozogamicin exposure in adults with acute myeloid leukemia does not increase hepatic veno-occlusive disease risk after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2020;26(5):884\u201392.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"19","key":"3217_CR28","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/cncr.30130","volume":"122","author":"S Giebel","year":"2016","unstructured":"Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122(19):2941\u201351.","journal-title":"Cancer"},{"issue":"10","key":"3217_CR29","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1111\/cas.14167","volume":"110","author":"Y Akahoshi","year":"2019","unstructured":"Akahoshi Y, Nishiwaki S, Mizuta S, Ohashi K, Uchida N, Tanaka M, et al. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Sci. 2019;110(10):3255\u20136.","journal-title":"Cancer Sci"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03217-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03217-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03217-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T12:04:25Z","timestamp":1642334665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03217-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3217"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03217-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"26 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors except the following have no conflict of interest to declare. TT reports personal fees from Otsuka, personal fees from Novartis, personal fees from Pfizer, personal fees from BMS, personal fees from Daiichi Sankyo, personal fees from Astellas, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}